Tango Therapeutics, Inc. (TNGX)

♥ 654 Thanks from members

Tango Therapeutics, Inc. (TNGX) exhibits strong Wall Street bullishness anchored by promising vopimetostat pancreatic cancer data and major price target hikes, contrasted with retail uncertainty, an earnings miss, zero collaboration revenue, and a $400 million ATM offering.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

Superior Group of Companies, Inc. (SGC)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

Entity & Market Metadata

Sector: Healthcare Industry: Biotechnology Founder: Third Rock Ventures Founder: Tango Therapeutics Team Leadership: Anurag Dua (CEO) Holder: Third Rock Ventures Holder: Baker Bros. Advisors Holder: Fidelity TNG908 PRMT5 Inhibitor Precision Oncology Pipeline #TNGX #Tango Therapeutics #Biotech #Synthetic Lethality #NASDAQ